STAT

FDA plans to speed path to approval for some gene therapies, starting with hemophilia

Hemophilia is the first disease the FDA will target with its new policy.
Source: AP Photo/Eric Risberg

WASHINGTON — The Food and Drug Administration will soon be alerting companies that certain gene therapies in development can qualify for less arduous review at the agency, Commissioner Scott Gottlieb said Tuesday.

Specifically, gene therapies for , a rare disease in which blood doesn’t

You're reading a preview, sign up to read more.

More from STAT

STAT1 min read
STAT Plus: Pharmalittle: Sanofi Walks Back Covid-19 Vaccine Remarks; Trump To Name Vaccine Czar With Conflicts
Sanofi insisted it would make its Covid-19 vaccine available in all countries, hours after chief executive Paul Hudson said the U.S. will get first access.
STAT1 min readSociety
STAT Plus: Pharmalittle: Hydroxychloroquine Fails To Help Patients In A Study; What Will States Do With The Old Malaria Drug Now?
After doubts arose about whether hydroxychloroquine is safe and effective for treating Covid-19, states are donating supplies to patients who need them to treat other illnesses or seeking refunds.
STAT1 min readSociety
STAT Plus: Pharmalittle: Administration Mishandled Initial Remdesivir Distribution; AstraZeneca Lung Cancer Drug Shows Big Benefit
The Trump administration mishandled the initial distribution of remedesivir, the experimental Gilead Sciences Covid-19 medicine, delaying treatment to some critically ill patients.